Brief Summary

Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years old who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were physician discretion.

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

14,032

participants targeted

Target at P75+ for all trials

Timeline

Completed

Started Nov 2012

Typical duration for all trials

Geographic Reach

1 country

107 active sites

Status

completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

2.3 years study duration

Study Start

First participant enrolled

November 1, 2012

Completed

11 days until next milestone

First Submitted

Initial submission to the registry

November 12, 2012

Completed

16 days until next milestone

First Posted

Study publicly available on registry

November 28, 2012

Completed

2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed

3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2015

Completed

Last Updated

December 11, 2015

Status Verified

December 1, 2015

Enrollment Period

2.1 years

First QC Date

November 12, 2012

Last Update Submit

December 10, 2015

Conditions

Coronary Artery Disease

Keywords

Coronary Artery Diseaseantiplatelet therapy

Outcome Measures

Primary Outcomes (1)

Major adverse cardiac and cerebral events
a composite of all cause death, myocardial infarction, stroke or any revascularization or stroke
12month

Secondary Outcomes (8)

all cause death
12month
Stent thrombosis
12 month
rehospitalization
12 month
any bleeding events
12 month
recurrent angina
12 month
+3 more secondary outcomes

Study Arms (1)

Antiplatelet therapy

patients with coronary artery disease receiving any antiplatelet therapy, without any intervention by the investigators.

Eligibility Criteria

Age18 Years - 85 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patient of coronary heart disease receiving any antiplatelet therapy

You may qualify if:

Clinical diagnosis of coronary heart disease
Age \>= 18 years old
receiving any antiplatelet agents
Informed written consent signed

You may not qualify if:

With severe disease and life expectancy for 6 months or less
Difficult to attain follow-up situations judged by researchers (travel, speech or mental disorder, etc.)
Taking part in an interventional clinical research

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Shenyang Northern Hospitallead
Guangdong Provincial People's Hospitalcollaborator

Study Sites (107)

The first affiliated hospital of Bengbu Medical College

Bengbu, Anhui, China

Location

Beijing Anzhen Hospital